| abstract |
The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) E1E2 heterodimer, HCV E2 or HCV E1; and b) an adjuvant, wherein the adjuvant is a cyclic dinucleoside acid or archaeal liposomes. The present disclosure provides methods of inducing an immune response to HCV in an individual comprising administering to the individual an effective amount of an immunogenic composition of the present disclosure. |